Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Developing a polygenic score to aid in the prediction of cisplatin-induced ototoxicity

FY 2020-21

Summary
Cisplatin is a common and effective chemotherapy drug which is used to treat many different types of cancer, and as with many chemotherapeutics, it harms both tumour and healthy cells. One of the most frequent adverse drug reactions seen with cisplatin is ototoxicity (hearing loss). Up to 80% of patients experience this adverse drug reaction and hearing loss is more commonly seen in pediatric cancer patients. As hearing loss impacts children's ability to develop critical language skills, this puts the patients at a disadvantage in educational and social settings. One method that can be used to predict who is most likely to suffer from cisplatin-induced ototoxicity (CIO) is the development of polygenic scores (PGS). Studies have shown that CIO has a genetic component that can be traced to multiple genetic variants. PGS would account for the genetic risks attributed to each of these genetic variants, to create a single risk prediction score for each patient. As the genetic architecture of CIO is similar to other forms of hearing loss, genetic variants that are significantly associated with heritable forms of hearing loss can be harnessed to develop a PGS for CIO. The relevance of this PGS for CIO will be increased by only including variants occurring in genes that are expressed in the inner ear, or which display a relationship with cisplatin-induced cell death. This project will be novel as it is the first study to use PGS to predict adverse drug reactions and will provide a way to improve the prediction of who is most likely to suffer from CIO. As cancer rates are steadily increasing, this project will allow for personalized treatment strategies to be developed which will help to reduce health care burdens in cancer survivors, especially in pediatric cancer patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449433
Name
Sarvis MacKenzie A
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a polygenic score to aid in the prediction of cisplatin-induced ototoxicity
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Audiology; Cisplatin-Induced Ototoxicity; Genome-Wide Association Study; Hearing Loss; Inner Hair Cells; Pediatric Oncology; Pharmacogenomics; Polygenic Scores; Precision Medicine
Abstract
Cisplatin is a common and effective chemotherapy drug which is used to treat many different types of cancer, and as with many chemotherapeutics, it harms both tumour and healthy cells. One of the most frequent adverse drug reactions seen with cisplatin is ototoxicity (hearing loss). Up to 80% of patients experience this adverse drug reaction and hearing loss is more commonly seen in pediatric cancer patients. As hearing loss impacts children's ability to develop critical language skills, this puts the patients at a disadvantage in educational and social settings. One method that can be used to predict who is most likely to suffer from cisplatin-induced ototoxicity (CIO) is the development of polygenic scores (PGS). Studies have shown that CIO has a genetic component that can be traced to multiple genetic variants. PGS would account for the genetic risks attributed to each of these genetic variants, to create a single risk prediction score for each patient. As the genetic architecture of CIO is similar to other forms of hearing loss, genetic variants that are significantly associated with heritable forms of hearing loss can be harnessed to develop a PGS for CIO. The relevance of this PGS for CIO will be increased by only including variants occurring in genes that are expressed in the inner ear, or which display a relationship with cisplatin-induced cell death. This project will be novel as it is the first study to use PGS to predict adverse drug reactions and will provide a way to improve the prediction of who is most likely to suffer from CIO. As cancer rates are steadily increasing, this project will allow for personalized treatment strategies to be developed which will help to reduce health care burdens in cancer survivors, especially in pediatric cancer patients.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sarvis, MacKenzie A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Manitoba - $17,500 Grant (2020-21) | Canada Spends